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Abstract.
Background: Circadian disruption has long been recognized as a symptom of Alzheimer’s disease (AD); however, emerging
data suggests that circadian dysfunction occurs early on in disease development, potentially preceding any noticeable cognitive
deficits.
Objective: This study compares the onset of AD in male and female wild type (C57BL6/J), transgenic (A␤PP/PS1), and
knock-in (APPNL-F/NL-F ) AD mouse models from the period of plaque initiation (6 months) through 12 months.
Methods: Rhythmic daily activity patterns, glucose sensitivity, cognitive function (Morris water maze, MWM), and AD
pathology (plaques formation) were assessed. A comparison was made across sexes.
Results: Sex-dependent hyperactivity in A␤PP/PS1 mice was observed. In comparison to C57BL/6J animals, 6-month-old
male A␤PP/PS1 demonstrated nighttime hyperactivity, as did 12-month-old females. Female A␤PP/PS1 animals performed
significantly worse on a MWM task than A␤PP/PS1 males at 12 months and trended toward increased plaque pathology.
APPNL-F/NL-F 12-month-old males performed significantly worse on the MWM task compared to 12-month-old females. Significantly greater plaque pathology occurred in A␤PP/PS1 animals as compared to APPNL-F/NL-F animals. Female A␤PP/PS1
animals performed significantly worse than APPNL-F/NL-F animals in spatial learning and memory tasks, though this was
reversed in males.
Conclusion: Taken together, this study provides novel insights into baseline sex differences, as well as characterizes baseline
diurnal activity variations, in the A␤PP/PS1 and APPNL-F/NL-F AD mouse models.
Keywords: Alzheimer’s disease, amyloid-␤, arginine vasopressin, circadian rhythm, cognition, glial fibrillary acidic protein,
metabolism, vasoactive intestinal peptide
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INTRODUCTION
As the average human life expectancy continues
to increase, so does the prevalence of non-communicable disease. Currently, 1 in 10 people within the
United States age 65 and older have Alzheimer’s
disease (AD) related dementia, with prevalence
increasing with age. AD is characterized by the
accumulation of amyloid-␤ (A␤) plaques and
neurofibrillary tau tangles, resulting in neurodegenerative processes that ultimately lead to progressive
cognitive deficiencies [1, 2]. In addition to cognitive decline, circadian system disruption is a notable
symptom in early AD development, often presenting
as disrupted sleep/wake rhythms as well as increased
restlessness and agitation toward dusk, termed “sundowning” [3, 4]. Circadian dysfunction may occur
several years prior to dementia diagnosis, but until
recently was characterized simply as a symptom of
disease progression [5]. Current literature, however,
suggests that circadian disruption may play a role in
AD pathogenesis.
On the circuit level, the mammalian circadian system is organized in a hierarchical manner, with the
suprachiasmatic nucleus (SCN) in the basal hypothalamus serving as the master oscillator, synchronizing
peripheral tissue oscillators to regulate local and
whole organism circadian physiology [6, 7]. The
SCN receives glutamatergic input onto vasoactive
intestinal peptide (VIP) containing neurons via the
retinal hypothalamic tract to synchronize rhythms
to the environmental 24-h light/dark cycle [8, 9].
These VIP-containing neurons provide interneuronal synchronization within the SCN to strengthen
overt circadian output [9–11]. Within the SCN,
arginine vasopressin (AVP)-containing neurons participate in generation of robust circadian rhythms
and determination of circadian period, primarily via
interneuronal coupling [12]. Of the many circadian
outputs that are measurable, day/night variations in
locomotor activity directly reflect diurnal biological
rhythms in the SCN [13–15]. In addition to increased
night-time activity and agitation, human AD patients
may also experience neuronal cell loss in the SCN,
specifically of AVP- and VIP-containing neurons,
presenting a potential mechanism by which circadian
dysfunction results from pathological progression
[16–18]. However, the relationship between AD and
circadian dysfunction is proving to be bidirectional,
indicating that circadian disturbances via chronic jetlag exposure or routine swing shifts in the workplace
have the capacity to contribute to AD pathogenesis.

Potential interactions include fluctuations in diurnal A␤ levels and glymphatic clearance, changes
in the astrogliotic response to plaque development,
disrupted cellular clocks and robust intracellular
synchrony, oxidative stress, and neurodegeneration
[19–22].
The A␤PP/PS1 transgenic mouse line is one of
the more commonly used animal models of AD. Initial plaque deposition is reported at around 6 months
and progresses with aging. In addition, A␤PP/PS1
mice do not form neurofibrillary tau tangles and
present little to no neuronal cell loss, allowing for a
focused approach to the role of A␤ in AD pathology
[23, 24]. Recently, a knock-in model (APPNLF/NLF )
expressing a mutant human amyloid precursor protein (A␤PP) gene under the endogenous mouse
A␤PP promoter has garnered attention [25]. The
APPNL-F/NL-F expresses a humanized A␤PP with
both the Swedish and Iberian mutations, resulting
in increased overall A␤40-42 production with preferential cleavage for A␤42 production, which is more
prone to the oligomerization and plaque formation
that is a hallmark in AD pathology [25, 26]. In
addition, the APPNL-F/NL-F expresses A␤PP with
the appropriate cell type and temporal specificity,
preventing the overproduction of other A␤PP fragments that have the potential to be biologically active,
thus further optimizing studies specific for examining A␤. The APPNL-F/NL-F is reported to develop
initial plaque deposition as early as 6 months, similar to A␤PP/PS1 animals [25]. The goal of this study
was to characterize differential diurnal activity patterns, metabolic, cognitive, and pathological changes
as a result of AD development between these two animal models from the early stages of AD pathology
to later stage disease development. In addition, both
male and female animals were used for each respective AD model. As nearly two-thirds of people within
the United States with AD are women, it is of high
importance to examine potential sex differences in
disease development that might occur in these two
commonly used animal models.
METHODS
Animals
Protocols for animal use were approved by the
Institutional Animal Care and Use Committee at Southern Illinois University School of Medicine. Eightweek-old male and female A␤PP/PS1 (RRID:M
MR RC034832-JAX; Mo/HuAPP695swe/PS1-dE9)
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mice, A␤PPNL-F/NL-F mice and controls (C57BL
6/J) (RRIF:IMSR JAX:000664) were group housed
and entrained to a control 12 : 12-h light: dark schedule with food and water ad libitum. Animals were
aged under control conditions to 6- and 12-month
endpoints. One month prior to the endpoint, animals
underwent glucose tolerance test (GTT), then were
individually housed and activity was monitored for
3 weeks measured using infrared-activity detectors
(Minimitter, Bend, OR). Activity data were collected
in 6-minute bins and analyzed using Clocklab
software (Actimetrics, Evanston, IL). Following
activity monitoring, mice underwent a Morris Water
Maze (MWM) cognitive assessment. Following
MWM, all animals were sacrificed at Zeitgeber time
(ZT) 12, defined as the time of lights off, via cervical dislocation. Whole brain tissue was collected
immediately following euthanasia and fixed in 4%
paraformaldehyde for 24 h, then transferred to 20%
sucrose for storage in 4◦ C.
Chemicals
All chemicals were prepared and stored according
to manufacturer recommendations unless otherwise
noted. Sodium chloride (Cat: 7647-14-5), Sucrose
(Cat: 57-50-1), Sodium phosphate Dibasic, Anhydrous (Cat: 7558-79-4), Potassium chloride (Cat:
7447-40-7), Dextrose (Cat: 50-99-7), and Bovine
serum albumin (Fraction V) (Cat: 9048-46-8) were
obtained from Thermo Fisher Scientific (Waltham,
MA). Potassium phosphate (Cat: 7778-77-01) was
obtained from Sigma-Aldrich Co. (St. Louis, MO).
Triton X-100 (Cat: 807426) and Sodium borohydride
(Cat: 102894) were obtained from MP Biomedicals
(Santa Ana, CA). Rabbit polyclonal VIP antibody
(Cat: 20077) and rabbit polyclonal AVP antibody
(Cat: 20069) were obtained from Immunostar (Hudson, WI). Chicken polyclonal glial fibrillary acidic
protein (GFAP) antibody (Cat: C-1373-50), AmyloGlo® RTD™ (Cat: TR-300-AG) were obtained from
Biosensis (Temecula, CA). Normal goat serum (Cat:
S26-LITER) was obtained from Millipore (Burlington, MA). Goat anti-chicken IgY H&L (Alexa Fluor®
594) (Cat: ab150172). Goat anti-rabbit IgG H&L
(Alexa Fluor® 594) (Cat: A11012) was obtained from
Invitrogen.
Intraperitoneal (IP) glucose tolerance test (GTT)
Initial blood glucose measurements were taken at
app. ZT 12 (time = 0) following a 15-h fast for GTT.
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Following the T = 0 measurement, a bolus of 20%
glucose was injected IP at 2 g of glucose/kg body
weight (b.w.). Blood glucose levels were then measured sequentially at 15, 30, 45, 60, and 120 min.
Glucose measurements were taken from blood collected from the tail vein using a Contour Next EZ
Glucometer (Parsippany, NJ).
Morris water maze
At either the 6- or 12-month randomly assigned
endpoints, mice underwent cognitive assessment of
spatial learning and memory recall using MWM.
The paradigm consists of distinct visual clues placed
around the room external to the maze borders by
which the animals were trained to utilize in finding
the location of a static, hidden platform (submerged
1 cm below an opaque water surface) across repeated
trials. The MWM paradigm consists of 5 consecutive training days (3 90-s trials/day) with a minimum
inter-trial-interval of 20 min. Starting quadrant was
randomized per trial among 3 starting locations with
no location repeated in a single day. Forty-eight hours
post-training, mice underwent a 60-s probe trial from
a singular starting location to determine memoryrecall. The Annulus 40 was defined as a region 40 cm
in diameter centered around the platform, which is
different from the annulus zone used to assess searching strategies in annular analysis of MWM [27].
ANY-maze video tracking system (Stoelting Co.,
Wood Dale, IL; RRID:SCR 014289) was used to
record animal navigation during the challenge and
probe trials. The 3 trials per day were averaged for
each animal in all analytical parameters. Mice were
excluded from MWM analysis if a > 75% improvement in learning was not observed by the 5th training
session due to implications that a lack of effective
learning would have on the memory task during the
probe trial. Number of animals excluded for each
group can be found in Supplementary Table 1.
Immunoﬂuorescence (IF) and analysis
20 m SCN and hippocampal sections were taken
using a cryostat (Model HM525 NX, ThermoFisher
Scientific). Serial sections were taken every 4th
section in the SCN and every 6th section in the
hippocampus. SCN sections underwent IF using rabbit polyclonal VIP antibody and rabbit polyclonal
AVP antibody. Sections were permeabilized in PBST
(0.1 M PBS with 0.25% TritonX-100) followed by
3 × 10-min washes in sodium borohydride in PBS

1080

J. Britz et al. / Assessing Sex-Speciﬁc Circadian, Metabolic, and Cognitive Phenotypes

(1 mg/ml) for antigen retrieval. To control for nonspecific binding, sections were washed 3 × 10 min
with PBST and incubated in 10%, normal goat
serum/1% BSA for 1 h. The sections were then incubated overnight in primary antibody in a humidity
chamber at 4◦ C. The following day, sections were
washed 4 × 10 min in PBST and incubated in secondary antibody Goat anti-rabbit IgG H&L (Alexa
Fluor® 594) 1 : 1000 for 2 h. The sections then underwent 1 final wash 4 × 10 min in PBST and were
coverslipped using ProLong™ Gold antifade reagent
with DAPI. Hippocampal sections underwent IF
using Chicken polyclonal glial fibrillary acidic protein (GFAP) antibody 1 : 1000, Amylo-Glo® RTD™
1 : 100. Prior to GFAP staining, slides were transferred to a 70% ethanol solution for 5 min followed
by a 2-min rinse in PBS. A 1 : 100 dilution of 100X
stock Amylo-Glo RTDTM was prepared fresh, and
the sections were incubated for 10 min in the staining solution. Slides were then rinsed in 0.9% saline
solution for 5 min without shaking and prepared for
IHC by rinsing 3 × 2 min in PBS. Goat anti-chicken
IgY H&L (Alexa Fluor® 594) 1 : 1000 was used as
the secondary. Amylo-Glo/GFAP slides were coverslipped using ProLong Gold™ antifade reagent.
Staining intensities for VIP, AVP, and GFAP were
measured using National Institute of Health Image
J Software 1.48 (RRID:SCR 003070). Similar areas
+/−10% were measured within each region of the
hippocampus for consistency. Images were captured
on a Nikon Eclipse E-600 microscope equipped with
an Olympus-750 video camera system, and a Dell
Pentium III computer. Approximately 4 section per
stain were obtained per animal. Staining density was
obtained when background staining was subtracted
from mean intensities. Amylo-Glo RTDTM stain was
analyzed using the same equipment; however, measurements were calibrated in Image J software and
recorded in mm2 .
Data analysis
Prism (GraphPad Software, Inc., La Jolla, CA;
RRID:SCR 002798) software was used for statistical analyses. For locomotor activity analysis, fasting
glucose, GTT AUC, and plaque number, a 2-way
ANOVA was used. MWM Platform: corrected integrated path length (CIPL) and Platform: Latency to
1st entry measurements were analyzed using a 2way ANOVA. Time spent in the annulus 40 and %
time in the target quadrant for the probe trial, AVP
and VIP mean fluorescence was analyzed using a

one-way ANOVA. When the ANOVA indicated statistical significance, a Tukey’s post-hoc test was used.
Data are represented as mean ± SEM and statistical
significance was defined as p < 0.05.
RESULTS
Sex-dependent hyperactivity and metabolic
changes in relation to aging in AβPP/PS1 mice
Considering the bidirectional relationship proposed between AD and circadian system dysfunction,
we sought to determine whether progressive AD
pathology impacted diurnal locomotor activity levels in our A␤PP/PS1 and APPNL-F/NL-F AD models.
Male and female A␤PP/PS1 mice, APPNL-F/NL-F
mice, alongside C57BL/6J controls were aged to
6- and 12-month endpoints to assess the impact
of progressive AD pathology from the onset of
plaque pathology outward on daily rhythmic activity, metabolism, and cognition. In female mice,
there was a significant main effect of animal group
(F5,184 = 4.574, p = 0.0006), as well as lighting conditions (F1,184 = 329.8, p < 0.0001.) in home cage activity. There was no interaction between animal group
and lighting conditions (F5,184 = 0.8876, p = 0.4906.)
In male mice, there was a significant main effect
of animal group (F5,142 = 2.563, p = 0.0297), as well
as lighting conditions (F1,142 = 329.8, p < 0.0001.) in
home cage activity. There was no interaction between
animal group and time of day (F5,184 = 0.8584,
p = 0.5108.) Lights off activity patterns were significantly higher than lights on activity patterns
within a group among all ages, sexes, and genotype.
Nighttime activity was not significantly dampened
with age under 12 : 12-h lighting conditions in
C57BL/6J mice. Home cage activity was unchanged
in 12-month-old C57BL/6J females as compared to
6-month-old C57BL/6J females. The ratio of lights
off/lights on activity in females was not significantly
changed as a result of aging in C57BL/6J females. In
male C57BL/6J mice, there was no change in activity levels or activity ratios from 6-12 months of age.
Similarly, no significant changes in diurnal activity
patterns were observed in A␤PP/PS1 mice of either
sex as a result of aging from 6–12 months. Alongside
A␤PP/PS1 animals, male and female APPNL-F/NL-F
mice were aged to 6- and 12-month endpoints to
assess the impact of progressive AD pathology on
rhythmic daily activity patterns. In comparison to
C57BL/6J mice, A␤PP/PS1 males displayed significant nighttime hyperactivity at 6 months. Similar
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Fig. 1. Diurnal activity patterns and glucose metabolism in aging and AD. Diurnal locomotor activity measurements in 6- and 12-month-old
male (A) and female (B) C57BL/6J, A␤PP/PS1, and APPNL-F/NL-F mice as measured via breakage of a cage-mounted infrared beam. Fasting
glucose following a 15-h fast in 6- and 12-month-old male (C) and female (E) C57BL/6J, A␤PP/PS1, and APPNL-F/NL-F mice. Glucose
tolerance as measured via area under the curve of blood glucose across 120 min following a bolus of 20% glucose administered ip. in male
(D) and female (F) C57BL/6J, A␤PP/PS1, and APPNL-F/NL-F mice. Sample sizes are noted in each respective figure. ∗ p < 0.05. # p < 0.05
with respect to lights off activity within a group.

A␤PP/PS1 hyperactivity was seen in females at 12
months as compared to C57BL/6J mice. In contrast,
APPNL-F/NL-F mice displayed comparatively similar
activity levels to controls (Fig. 1A, B).
Aging is associated with impaired glucose metabolism and progressive metabolic dysfunction in both
males and females [28, 29]. Additionally, comorbidity between AD and type-2 diabetes is highly
prevalent, thus it was our goal to characterize changes
in glucose metabolism, as well as sex differences in
the impact of aging from 6–12 months on metabolic
function in the A␤PP/PS1 and APPNL-F/NL-F AD
models [30, 31]. In female mice, a significant
main effect of genotype was observed in fasting
glucose levels (F2,90 = 5.885, p = 0.004) and GTT
AUC measurements (F2,90 = 4.025, p = 0.0212). In
male mice, there is a significant main effect of
both age (F1,74 = 5.038, p = 0.0278) and genotype
(F2,74 = 3.167, p = 0.0479) on fasting glucose levels,
however not on GTT AUC measurements. A significant interaction was observed between genotype
and age in both female (F2,90 = 3.447, p = 0.0361)
and male (F2,73 = 3.279, p = 0.0433 GTT AUC measurements). Fasting glucose levels as well as AUC
measurements remained unaltered as a result of aging
from 6–12 months in both male and female C57BL/6J
and APPNL-F/NL-F mice. Similarly, fasting glucose
or AUC measurements were not changed from 6–12
months in A␤PP/PS1 females. Male A␤PP/PS1 animals, however, presented higher fasting glucose

measurements at 12 months as compared to 6 months
(Fig. 1C–F). 12-month-old female A␤PP/PS1 mice
presented significantly higher fasting glucose levels as compared to age- and sex-matched C57BL/6J
mice. Similarly, female A␤PP/PS1 demonstrated
higher AUC measurements during the GTT at 6
months as compared to age- and sex-matched C67BL/
6J mice.
AD pathology progresses in a sex-dependent
manner in AβPP/PS1 mice
MWM was used to assess spatial learning and
memory recall on all mice (Fig. 2). During the 5day training session, a significant main effect in
platform: CIPL was observed from day 1 to day
5 (F4,160 = 36.21, p < 0.0001), indicating that all
groups were able to effectively learn the location
of the hidden platform. A significant main effect
of animals group was also observed on platform:
CIPL (F3,160 = 9.783, p < 0.0001). No interaction
between animal group and trial day across the
5-day training period was observed in platform:
CIPL measurements (F12,160 = 0.761, p = 0.6896).
12-month-old female A␤PP/PS1 mice presented significantly higher platform: CIPL measurements as
compared to 6-month-old A␤PP/PS1 female mice
on day 3. On day 1 and day 3 of the 5-day training
period, 12-month-old females presented significantly
higher CIPL measurements than 12-month-old males
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Fig. 2. MWM training and probe challenge in A␤PP/PS1 mice. Data from each of the 3 trials were averaged for each respective day of the
5-day training period. Probe data consists of a single 60-s trial. A) Platform: CIPL during the 5-day training period. B) Latency to 1st entry
to the platform during the 5-day training period. C) Platform: CIPL during the probe trial. D) Percent time spent in the target quadrant during
the probe trial. E) Total time spent in the annulus 40 during the probe trial. Sample Sizes for MWM are noted in the probe trial. ♂
♀ p < 0.05
between sexes at the indicated age. # p < 0.05 between age groups within a sex.

(Fig. 2A). On the remaining training days, a similar
trend of females presenting higher CIPL than males
at 12 months was apparent, though did not reach
significance. Day 1 differences could potentially be
attributed to differences in short term memory, as
data for each day is averaged across 3 independent
trials. No significant differences were observed in
latency to 1st entry to the platform location across
training days in A␤PP/PS1 mice (F3,160 = 2.553,
p = 0.0574), though a significant main effect of
latency to 1st entry was observed, indicating all
groups had learned the location of the hidden platform
(F4,160 = 24.02, p < 0.0001) (Fig. 2B). No interaction between animal group and trial day across the
5-day training period was observed in latency to
1st platform entry measurements (F12,160 = 0.9468,
p = 0.5021). No differences were found in the probe
trial within a sex from 6–12 months, as measured by percent time spent in the target quadrant
(F3,32 = 0.2024, p = 0.8939), time spent in the annulus 40 (F3,32 = 0.2041, p = 0.8928), and CIPL from the
platform area (F3,32 = 2.38, p = 0.0874) (Fig. 2C–E).
No significant difference was observed between sexes
in 12-month-old C57BL/6J animals on the MWM
task, indicating the differences observed here are

a result of sex-dependent effects on learning and
memory as a result of AD phenotype at the 12-month
endpoint (Supplementary Figure 1).
A␤ plaque burden was analyzed via total plaque
number in each subregion of the hippocampus
(dentate gyrus (DG), CA1, CA3) (Fig. 3). A
main effect of age (F1,15 = 137.6, p < 0.0001) and
hippocampal subregion (F2,15 = 18.67, p < 0.0001)
was observed in female A␤PP/PS1 mice on hippocampal plaque number. A significant interaction
was also observed between age and hippocampal subregion on hippocampal plaque number
(F2,15 = 10.34, p = 0.0015). Similarly, a main effect
of age (F1,15 = 12.63, p = 0.0023) and hippocampal
subregion (F2,15 = 4.989, p = 0.0189) was observed
in female A␤PP/PS1 mice on hippocampal plaque
number. Plaque number was significantly higher at
the 12-month endpoint as compared to 6-month-old
animals in both male and female A␤PP/PS1 mice
across hippocampal subregions (Fig. 3A–C).
A main effect of age (F1,12 = 16.11, p = 0.0017)
was observed in female A␤PP/PS1 mice on hippocampal GFAP expression. A main effect of age
(F1,12 = 17.93, p = 0.0012) and hippocampal subregion (F2,12 = 8.329, p = 0.0054) was observed in
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Fig. 3. Plaque pathology and astrogliotic response in the A␤PP/PS1 AD model. A) Representative plaque progression in the DG, CA1,
and CA3 hippocampal subregions in male and female A␤PP/PS1 animals from 6–12 months (10x magnification, scale bar = 100 m).
Average plaque number was quantitated for (B) females and (C) males across hippocampal subregions. D) Hippocampal astrocyte reactivity via GFAP IF (10x magnification, scale bar 50 m). E) Representative astrogliotic response to amyloid plaques in a
12-month-old female A␤PP/PS1 mouse (20x magnification, scale bar = 20 m). Average mean fluorescence for GFAP IF was quantitated across hippocampal subregions in (F) female and (G) male A␤PP/PS1 mice. N = 3–4 for all groups. ∗ p < 0.05, ∗∗ p < 0.01,
∗∗∗∗ p < 0.0001.

female A␤PP/PS1 mice. No interaction between age
and hippocampal subregion was observed in female
(F2,12 = 3.621, p = 0.0588) or male (F2,12 = 0.2443,
p = 0.787) A␤PP/PS1 mice. GFAP expression was
significantly higher at 12 months in the DG as
compared to 6 months in A␤PP/PS1 females and
significantly higher in DG and CA1 in 12-monthold males as compared to 6 months (Fig. 3D, F, G).
Though not statistically significant, plaque pathology in females trended at higher levels than males
at the 12-month endpoint (Supplementary Figure 2).
Merged images illustrate the astrogliotic response
around plaque regions that was present at plaque sites
of all cohorts (Fig. 3E).

Comparative AD phenotype and diurnal activity
patterns between an APPNL-F/NL-F knock-in
model and the AβPP/PS1 transgenic line
In APPNL-F/NL-F mice, no significant differences
were found from 6–12 months in male or female mice
as measured by platform: CIPL and latency to 1st
entry to the platform location during the 5-day training session. There was, however, a significant main
effect of platform: CIPL (F4,175 = 50.42, p < 0.0001)
and latency to 1st platform entry (F4,180 = 16.96,
p < 0.0001), indicating all groups learned the location
of the hidden platform. Memory recall was significantly dampened in 12-month-old APPNL-F/NL-F
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Fig. 4. MWM training and probe challenge in APPNL-F/NL-F mice. A) Data from each of the 3 trials were averaged for each respective day
of the 5-day training period. Probe data consists of a single 60-s trial. A) CIPL during the 5-day training period. B) Latency to 1st entry to
the platform during the 5-day training period. C) Platform: CIPL during the probe trial. D) Percent time spent in the target quadrant during
the probe trial. E) Total time spent in the annulus 40 during the probe trial. Sample Sizes for MWM are noted in the probe trial. ∗ p < 0.05.

males as compared to 12-month-old females, as measured by percent time spent in the target quadrant
(F3,36 = 3.288, p = 0.0316), though differences in time
spent in the annulus 40 did not significantly differ
during the probe trial (Fig. 4D, E). No significant
differences were found in platform: CIPL during the
probe trial (Fig. 4C). Similar learning curves, in addition to statistically similar CIPL values on day 5 of
the training phase suggests a similar spatial learning
capacity, making both groups directly comparable for
the day 8 probe challenge. Differences observed in
the percent time spent in the target quadrant during
the probe trial suggests dampened memory recall in
males as compared to females in the APPNL-F/NL-F
AD model at 12 months.
Six-month-old male AD models performed similarly during the 5-day training phase (Fig. 5B, F). A
significant main effect of genotype (F2,190 = 7.673,
p = 0.0006) and trial day (F4,190 = 54.72, p < 0.0001)
was observed in 6-month-old females, with no
interaction between genotype and trial day on platform: CIPL measurements through the 5-day training
period in 6-month-old females (F8,190 = 0.8069,
p = 0.5972). Similarly, a significant main effect
of genotype (F2,210 = 12.86, p < 0.0001) and trial
day (F4,210 = 16.23, p < 0.0001) was observed in
6-month-old females, with no interaction between

genotype and trial day on latency to 1st entry to the
platform location through the 5-day training period
in 6-month-old females (F8,210 = 0.2791, p = 0.9723).
A post-hoc analysis revealed that in 6-month-old
females, APPNL-F/NL-F mice presented a significantly higher platform: CIPL value on day 1 as
compared to C57BL/6J mice, and A␤PP/PS1 mice
presented an increased latency to 1st platform entry
on day 1 and day 5 as compared to C57BL/6J mice
(Fig. 5A, E). Total time spent in the annulus 40 and
percent time spent in the target quadrant during the
probe trial was not significantly different between
genotypes in either sex or endpoint (Fig. 5C, D, G, H).
A significant main effect of genotype (F2,190 =
7.673, p = 0.0006) and trial day (F4,190 = 54.72,
p < 0.0001) was observed in 12-month-old females,
with no interaction between genotype and trial day
on platform: CIPL measurements through the 5day training period in 6-month-old females (F8,190 =
0.8069, p = 0.5972). Similarly, a significant main
effect of genotype (F2,165 = 8.612, p = 0.0003) and
trial day (F4,165 = 20.86, p < 0.0001) was observed in
12-month-old females, with no interaction between
genotype and trial day on latency to 1st entry
to the platform location through the 5-day training period in 6-month-old females (F8,165 = 0.7166,
p = 0.6767). In 12-month-old females, A␤PP/PS1
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Fig. 5. Comparative cognitive decline in 6-month-old A␤PP/PS1 and APPNL-F/NL-F AD models. Platform: CIPL and latency to 1st platform
entry was averaged across 3 independent trials per day during the 5-day training period. Probe (day 8) data was taken from a single 60-s trial.
Platform: CIPL during the 5-day training period is represented in 6-month-old females (A), 6-month-old males (B). Latency to 1st platform
entry is represented in 6-month-old females (E), and 6-month-old males (F). Percent time spent in the target quadrant during the probe trial
is represented in 6-month-old females (C), 6-month-old males (D). Time spent in the annulus 40 during the probe trial is represented in
6-month-old females (G), and 6-month-old males (H). Sample Sizes for MWM are noted in C-H. ∗ p < 0.05 with respect to C57BL/6J, color
coordinated for the group being compared.

animals showed significantly higher platform: CIPL
and latency to 1st platform entry values in MWM on
day 3 and 5 on the training session over C57BL/6J
controls, and significantly above APPNL-F/NL-F mice
on day 3, suggesting significantly delayed spatial
learning in A␤PP/PS1 females at 12 months that
was not present in APPNL-F/NL-F mice (Fig. 6A,
E). Male A␤PP/PS1 mice performed similarly to
C57BL/6J animals at 12 months, suggesting differential rates of cognitive decline between A␤PP/PS1
males and females (Fig. 6B, F). A significant main
effect of genotype (F2,135 = 6.829, p = 0.0015) and
trial day (F4,135 = 4.593, p = 0.0017) was observed in
12-month-old females, with no interaction between
genotype and trial day on latency to 1st entry to the
platform location through the 5-day training period
in 6-month-old females (F8,135 = 1.38, p = 0.2108). In
12-month-old males, APPNL-F/NL-F mice presented
an increased latency to 1st platform entry on day
5 over A␤PP/PS1 mice. No significant differences
in time spent in the target quadrant and annulus 40

during the probe trial were observed (Fig. 6D, F, H).
No significant differences were observed in platform:
CIPL across the 5-day training phase between either
AD model and C57BL/6J controls in 12-month-old
males (Fig. 6B).
Similar to the A␤PP/PS1 animals, a significant
main effect of age (F1,18 = 12.54, p = 0.0023) and
hippocampal subregion (F2,18 = 4.629, p = 0.0239)
was observed in female APPNL-F/NL-F mice on
hippocampal plaque number, with no significant
interaction between age and hippocampal subregion
(F2,18 = 2.743, p = 0.0913). Increased plaque burden
in the APPNL-F/NL-F mice from 6 to 12 months
was significant in females, but not males. It should,
however, be noted that at 6 months, hippocampal
plaque burden was minimal in the APPNL-F/NL-F AD
model (Fig. 7A–C). In 12-month-old APPNL-F/NL-F
males, there was a significant main effect of age on
GFAP expression in the hippocampus (F1,12 = 12.26,
p = 0.0044). 12-month-old male GFAP expression
was significantly higher in the CA1 as compared to
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Fig. 6. Comparative cognitive decline in 12-month A␤PP/PS1 and APPNL-F/NL-F AD models. Platform: CIPL and latency to 1st platform
entry was averaged across 3 independent trials per day during the 5-day training period. Probe (day 8) data was taken from a single 60-s
trial. Platform: CIPL during the 5-day training period is represented in 12-month-old females (A), 12-month-old males (B). Latency to 1st
platform entry is represented in 12-month-old females (E), and 12-month-old males (F). Percent time spent in the target quadrant during
the probe trial is represented in 12-month-old females (C), 12-month-old males (D). Time spent in the annulus 40 during the probe trial is
represented in 12-month-old females (G), and 12-mont-oldh males (H). Sample Sizes for MWM are noted in C-H. ∗ p < 0.05 with respect to
C57BL/6J, color coordinated for the group being compared. ∗∗ p < 0.05 A␤PP/PS1 versus APPNL-F/NL-F .

6-month-old males. No significant differences were
found in GFAP expression from 6–12 months in
APPNL-F/NL-F females (Fig. 7D–F). Sex- and agematched A␤PP/PS1 animals presented significantly
more plaque burden than APPNL-F/NL-F animals,
indicating differential rates of AD pathological progression between these two models (Fig. 8A–F). In
6-month-old females, there was a significant main
effect of genotype (F1,18 = 13.52, p = 0.0017) and
hippocampal subregion (F2,18 = 3.990, p = 0.0368)
on hippocampal amyloid plaque number, with no
significant interaction between genotype and hippocampal subregion (F2,18 = 3.107, p = 0.0693). In
6-month-old males, there was a significant main
effect of genotype (F1,18 = 4.799, p = 0.0419) on hippocampal amyloid plaque burden. In 12-month-old
females, there was a significant main effect of genotype (F1,15 = 193.7, p < 0.0001) and hippocampal
subregion (F2,15 = 19.73, p < 0.0001) on hippocampal amyloid plaque number, with a significant

interaction between genotype and hippocampal subregion (F2,12 = 14.53, p = 0.0003). In 12-month-old
males, there was a significant main effect of genotype (F1,18 = 20.42, p = 0.0003) and hippocampal
subregion (F2,18 = 3.875, p = 0.0398) on hippocampal
amyloid plaque number, with no significant interaction between genotype and hippocampal subregion
(F2,18 = 3.138, p = 0.0678).
AVP and VIP expression in the SCN were measured via immunofluorescence in 6- and 12-monthold A␤PP/PS1 mice of both sexes to determine if
any circadian effects seen in our AD models were
a result of circadian relevant neuropeptide loss. No
significant differences were found as a result of AD
progression in expression of either neuropeptide in
comparison to C57BL/6J controls in either females
(Fig. 9A–D) or males (Fig. 9E–H) by the 12-month
time point. Similarly, there were no sex differences in
AVP or VIP expression in either AD model at either
the 6 or 12-month endpoints.
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Fig. 7. Plaque pathology and astrogliotic response in the APPNL-F/NL-F AD model. A) Representative plaque progression in the DG, CA1,
and CA3 hippocampal subregions in male and female APPNL-F/NL-F animals from 6–12 months (10x magnification, scale bar = 100 m).
Average plaque number was quantitated for (B) females and (C) males across hippocampal subregions. D) Hippocampal astrocyte reactivity
via GFAP IF (10x magnification, scale bar 50 m). Average mean fluorescence for GFAP IF was quantitated across hippocampal subregions
in (E) female and (F) male APPNL-F/NL-F mice. N = 3–4 for all groups. ∗ p < 0.05, ∗∗ p < 0.01.

DISCUSSION
Increased hippocampal plaque burden in 12month-old female A␤PP/PS1 animals over 12month-old males approached significance, correlating with previous studies in the cerebellum that
indicated a 5–10 fold increase in free A␤42 and
A␤40 as well as plaque deposition, though this sex
difference was not present in cortex [32]. Independent of sex, there was significantly higher plaque
deposition at 12 months as compared to 6 months,
though did not reach significance in all hippocampal subregions. Age-related progression of amyloid
deposition in A␤PP/PS1 mice followed a similar
pattern to previous studies whereby accumulation

was first observed in the CA1 followed by DG and
finally the CA3 [33]. Significant differences in plaque
pathology were at times observed in some subregions
of the hippocampus and not others. In the case of
comparisons inclusive of APPNL-F/NL-F , there was
very little plaque pathology, even at the 12-month
endpoint. In many circumstances, plaques existed
clustered around a single point, presenting values
under 5 for a whole subregion. If there was no such
cluster, the value was often zero for a particular region
in a particular sample. This created enhanced variability that could account for the lack of statistical
significance in one subregion over another. There
is very little data regarding the specific initiation
of plaque pathology in one hippocampal subregion
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Fig. 8. Comparative plaque pathology between A␤PP/PS1 and the APPNL-F/NL-F AD models. A) Comparative plaque pathology in female
mice at both 6- and 12-month endpoints across the DG, CA1, and CA3 hippocampal subregions (10x magnification, scale bar 100 m).
Average plaque number across hippocampal subregions was quantitated in (B) 6-month-old females and (C) 12-month-old females. D)
Comparative plaque pathology in male mice at both 6- and 12-month-old endpoints across the DG, CA1, and CA3 hippocampal subregions.
Average plaque number across hippocampal subregions was quantitated in (E) 6-month-old males and (F) 12-month-old males. N = 3–4 for
all groups. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001.

over another, particularly in the mouse models used
for this study. Additionally, it is unclear if there are
differences between strains in the spatial and temporal progression of plaque pathology throughout brain
regions, and especially specific hippocampal subregions. Spatial and temporal progression of amyloid
plaques in AD in humans observed plaque deposition
in early Braak stages in the CA1, only presenting in the CA3 in latter stages [34]. This could
explain why significance is often found in CA1 and
DG, whereas the CA3 presents lesser plaque pathology, and thus may not change much from the age
of plaque initiation by the endpoints used in this
study.

A general increase in hippocampal reactive astrocytes, as measured via GFAP expression, was
observed in A␤PP/PS1 mice similar to previous
studies [31]. The role of reactive astrocytes in AD
pathology remains heavily debated. Astrocyte reactivity is heavily correlated with progressive plaque
formation in AD, and it has been hypothesized that
reactive astrocytes potentially contribute to plaque
formation via upregulation of ␤-secretase, promoting cleavage of A␤PP and amyloid formation [35].
Evidence also exists suggesting that astrocyte reactivity can impact synaptic function and enhance
excitotoxicity through a downregulation of GLT-1
and glutamine synthetase [36]. This may partially
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Fig. 9. Comparative 12-month AVP and VIP expression. Representative AVP images from the SCN of 12-month-old (A) female and (E)
male C57BL6J, A␤PP/PS1 and APPNL-F/NL-F animals. Mean Fluorescent intensity of for AVP expression in (B) females and (F) males.
Representative VIP images from the SCN of 12-month-old (C) female and (G) male C57BL6J, A␤PP/PS1 and APPNL-F/NL-F animals. Mean
Fluorescent intensity of for VIP expression in (D) females and (H) males. N = 3–4 for all groups. Scale Bar represents 100 m. All images
taken at 10x magnification.

account for the elevated hippocampal glutamate levels observed in A␤PP/PS1 mice [33, 37]. Conversely,
analysis of postmortem brain has shown that reactive
astrocytes absorb A␤ [38, 39]. This suggests a mechanism by which astrocytes participate in A␤ clearance
and mitigate plaque formation, either via secretion
of A␤ degrading enzymes or potential phagocytosis.
Katsouri et al. demonstrated that ablation of reactive
astrocytes in the A␤PP23/GFAP-TK mouse model
of AD exacerbated disease pathology as shown by
increased plaque pathology, cognitive deficiencies,
and enhanced neuroinflammation [40]. Astrocytes
also have an intricate relationship with the circadian system. Astrocytes are known to present daily
rhythms, and rhythmic activity of astrocytes within
the SCN has been shown to impact behavioral rhythmic output as shown via specific astrocytic deletion
of the clock gene Bmal1 or the CK1 tau mutation,
both of which lengthen the circadian period in clock

gene expression and locomotor activity by targeting
the cellular core clock machinery [41]. YKL-40, an
astrocytic protein that increases with age and AD
development, and has an inverse correlation with
astrocytic phagocytosis of A␤, is circadian-regulated
[42]. Astrocytes present circadian patterns of proximity to synapses and dendritic branching, impacting
hippocampal dependent learning and synaptic plasticity, presenting further possible implications of
circadian disturbances in AD progression [43].
Aging has been associated with a multitude of
circadian changes, including sleep fragmentation,
dysynchrony between central and peripheral oscillators, altered light sensitivity and ability to entrain
to shifting light cues, and a decline in amplitude and
robustness of overt behavioral rhythms such as locomotor activity [44–46]. AVP- and VIP-containing
neurons in the SCN are subject to neurodegeneration
in later stage AD, thus it was important to determine
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whether changes in locomotor activity during the
active period might be due to a change in expression of these peptides [16–18]. VIP neurons in the
core of the SCN are directly responsive to light cues,
and in vivo silencing of these neurons dampens reentrainment patterns to resetting cues via changes in
rhythmic light exposure [47, 48]. In the 3xTg mouse
model of AD, which develops both A␤ and tau pathology, a decrease in both AVP and VIP expression was
found at 11 months, prompting the question of at
what point through disease development this initiates, and if specific neuropeptide loss occurs across
animal models of AD [49]. AVP neurons in the SCN
shell are responsible for interneuronal synchronization between independently self-oscillating neurons,
driving robust rhythmic neuronal firing patterns [12].
We did not see any significant differences in either
of these neuropeptides at 6 or 12 months between
our AD models and C57BL/6J controls of either sex.
Additionally, we did not find any significant changes
in AVP or VIP from 6–12 months in either of the AD
models used in this study. It would be interesting to
determine if chronic circadian disruption throughout
disease development could serve as a second insult
to exacerbate AVP and VIP loss in the SCN.
Interstitial fluid (ISF) free A␤ levels have a diurnal rhythmicity. Chronic circadian disruption could
potentially impact rhythmic fluctuations in ISF A␤
levels and amyloid clearance [19, 20]. Additionally, multiple genes involved in A␤PP processing
are circadian rhythmic [50]. Similarly, forced sleep
disturbances in an A␤PP/PS1 AD mouse model
increased plaque burden, while increased sleep pressure via an orexin receptor antagonist reduced plaque
formation [19, 21]. Though there is not an abundance of research describing the potential role of
circadian rhythms as a contributing factor to AD
development, future studies manipulating the circadian system throughout AD development could be
beneficial in elucidating potential mechanisms.
The onset of cognitive impairment in A␤PP/PS1
animals is reported to occur around 12 months, thus
the lack of significance in males from 6–12 months in
MWM performance was not surprising [51]. Females
had significantly higher platform CIPL values during
the 5-day training phase as compared to males at 12
months of age, and there were significantly higher
CIPL values in 12-month-old females as compared
to 6-month-old females on day 3. Similarly, trending
data indicated an increased time spent in the annulus 40 in the probe trial in 12-month-old males as
compared to females, indicating dampened spatial

memory in females. The significant increases in Day
3 Platform: CIPL and Latency to 1st platform entry in
C57BL/6J animals above both AD models was surprising, though at 6 months of age, highly significant
learning and memory deficits were not expected in
either AD model. Additionally, all groups were statistically similar by day 5 of the 5-day training phase,
indicating that all groups had effectively learned the
location of the platform.
The correlation between aging and the development of metabolic syndrome has been well
established; however, sex dependent differences in
how aging impacts glucose are still being studied
and remain highly significant for the development
of sex-dependent therapeutic strategies [28]. Though
statistically nonsignificant, the trending drop in glucose tolerance in females from 6–12 months is
consistent with the number of biological changes
that occur in females between the 6- and 12-month
time points impacting glucose homeostasis, specifically the sharp drop that occurs in estrogen levels
upon reproductive senescence at approximately 9–12
months in mice [52–54]. Studies suggest a potential
link for altered insulin signaling and AD development, including accelerated A␤ accumulation,
elevated hippocampal glutamate, and increased neuroinflammation [31, 55]. While our results did not
elucidate any effect of progressive AD pathology in
female A␤PP/PS1 animals from 6–12 months, male
animals did present higher fasting glucose levels at
12 months as compared to 6 months, contrasting the
lack of an effect of aging in male C57BL/6J animals.
Using both the A␤PP/PS1 and the APPNL-F/NL-F
AD models provided useful insight as to how these
models compare in terms of AD pathology, cognitive decline, and circadian function. Additionally, the
use of both male and female animals presented novel
findings regarding sex differences in these models.
The use of the APPNL-F/NL-F knock-in models could
potentially serve to elucidate specific effects of A␤
going forward, as this model does not rely on the
tremendous overexpression and cleavage of A␤PP,
leading to other potentially physiologically active
A␤PP fragments. While the APPNL-F/NL-F presented
similar plaque pathology as the A␤PP model at 6
months, there were clear differential rates of progression between the two models up to the 12-month
endpoint. Of particular interest were the differential sex differences between these two models in the
memory recall portion of the MWM cognitive assessment. While some sex differences have been reported
in the A␤PP/PS1 model regarding A␤ production,
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the APPNL-F/NL-F model is relatively new, and significant sex differences in cognitive performance on
the MWM task have not been previously reported
[25, 32]. Considering the slow rate of plaque development in the APPNL-F/NL-F model, it would be worth
assessing potential sex differences in plaque pathology at a later age. Incorporating a characterization of
sex differences in these models as well as a side-byside comparison of pathological progression and AD
phenotype provides useful data for model choice in
future studies as well as dissecting the role of sex in
AD development.
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